Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease

Table 1 Characteristics of subjects.

Fibrosis	n	M/F	Age (yr)	Platelet (×104/mm3)	Albumin (g/L)	ALT (nkat/L)
F 0	5	3/2	35	19.9	42	182.6
			(29-39)	(14.4-26.0)	(3.2-4.6)	(7-84)
F 1	27	17/10	51	15.8	41	1477.4
			(31-73)	(10.3-25.2)	(3.6-4.7)	(20-267)
F 2	13	8/5	57	13	39	1543.8
			(50-64)	(10.0-15.1)	(3.5-4.5)	(31-235)
F 3	34	22/12	55	12.2	39	1062.4
			(30-68)	(8.3-19.1)	(3.3-4.3)	(23-295)
F 4	30	12/18	59	9.5	34	996
			(43-75)	(3.2-21.3)	(2.5-4.1)	(13-150)

M: male, F: female.